{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Secondary+Neoplasm&page=2",
    "query": {
      "condition": "Secondary Neoplasm",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Secondary+Neoplasm&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-27T02:03:41.408Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00251485",
      "title": "A Phase II Trial of Modified FOLFOX 6 and Cetuximab in First Line Treatment of Metastatic Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Cetuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Veeda Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 82,
      "start_date": "2004-03",
      "completion_date": "2005-06",
      "has_results": false,
      "last_update_posted_date": "2008-08-21",
      "last_synced_at": "2026-06-27T02:03:41.408Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00251485"
    },
    {
      "nct_id": "NCT01106508",
      "title": "A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Recurrent or Refractory Medulloblastoma",
        "Locally Advanced or Metastatic Basal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "LEQ506",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2010-10",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2020-12-17",
      "last_synced_at": "2026-06-27T02:03:41.408Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • New York, New York",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01106508"
    },
    {
      "nct_id": "NCT00032825",
      "title": "Ketoconazole Plus Docetaxel to Treat Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "Ketaconazole",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 674,
      "start_date": "2002-03-19",
      "completion_date": "2011-06-13",
      "has_results": false,
      "last_update_posted_date": "2019-11-21",
      "last_synced_at": "2026-06-27T02:03:41.408Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00032825"
    },
    {
      "nct_id": "NCT01140776",
      "title": "Clinical Evaluation of OSNA Breast Cancer System in Breast Cancer Patients Receiving Neoadjuvant Therapy",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Neoplasms",
        "Breast Diseases"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Sysmex America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2010-11",
      "completion_date": "2012-07",
      "has_results": false,
      "last_update_posted_date": "2011-06-07",
      "last_synced_at": "2026-06-27T02:03:41.408Z",
      "location_count": 2,
      "location_summary": "Tucson, Arizona • Houston, Texas",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01140776"
    },
    {
      "nct_id": "NCT06826768",
      "title": "A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "REGN5678",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 60,
      "start_date": "2025-07-09",
      "completion_date": "2029-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-06-27T02:03:41.408Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06826768"
    },
    {
      "nct_id": "NCT00019097",
      "title": "Vaccine Therapy in Treating Patients With Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage II Multiple Myeloma",
        "Stage III Multiple Myeloma",
        "Refractory Plasma Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "autologous tumor cell vaccine",
          "type": "DRUG"
        },
        {
          "name": "keyhole limpet hemocyanin",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "sargramostim",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1995-07",
      "completion_date": "2007-03",
      "has_results": false,
      "last_update_posted_date": "2024-03-04",
      "last_synced_at": "2026-06-27T02:03:41.408Z",
      "location_count": 3,
      "location_summary": "Little Rock, Arkansas • Bethesda, Maryland",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00019097"
    },
    {
      "nct_id": "NCT01765582",
      "title": "Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Neoplasms"
      ],
      "interventions": [
        {
          "name": "5-fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "capecitabine",
          "type": "DRUG"
        },
        {
          "name": "irinotecan",
          "type": "DRUG"
        },
        {
          "name": "folinic acid",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 280,
      "start_date": "2013-01-23",
      "completion_date": "2016-03-14",
      "has_results": true,
      "last_update_posted_date": "2017-09-18",
      "last_synced_at": "2026-06-27T02:03:41.408Z",
      "location_count": 45,
      "location_summary": "Mobile, Alabama • Long Beach, California • Los Angeles, California + 41 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Monterey",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01765582"
    },
    {
      "nct_id": "NCT04120246",
      "title": "Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "HER2 Positive Breast Carcinoma",
        "Metastatic Breast Carcinoma",
        "Refractory Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Alpha-tocopheryloxyacetic Acid",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Veana Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2020-04-08",
      "completion_date": "2030-02-01",
      "has_results": false,
      "last_update_posted_date": "2024-07-10",
      "last_synced_at": "2026-06-27T02:03:41.408Z",
      "location_count": 2,
      "location_summary": "Portland, Oregon • Seattle, Washington",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04120246"
    },
    {
      "nct_id": "NCT02892123",
      "title": "Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2-expressing Cancers"
      ],
      "interventions": [
        {
          "name": "ZW25 (Zanidatamab)",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Vinorelbine",
          "type": "DRUG"
        },
        {
          "name": "Tucatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jazz Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 279,
      "start_date": "2016-09-30",
      "completion_date": "2024-10-31",
      "has_results": false,
      "last_update_posted_date": "2024-11-27",
      "last_synced_at": "2026-06-27T02:03:41.408Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02892123"
    },
    {
      "nct_id": "NCT00428220",
      "title": "A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "Advanced Breast Cancer",
        "Metastatic Castration Resistant Prostate Cancer",
        "Metastatic Renal Cell Cancer",
        "Non-Small Cell Lung Cancer",
        "Thyroid Cancer",
        "Advanced/Metastatic Non-Small Cell Lung Cancer",
        "Advanced Gastric Cancer",
        "Gastrointestinal Stromal Tumor",
        "Hepatocellular Carcinoma",
        "Pancreatic Islet Cell Carcinoma",
        "Pancreatic Neuroendocrine Tumor"
      ],
      "interventions": [
        {
          "name": "sunitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 223,
      "start_date": "2007-07",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2019-06-27",
      "last_synced_at": "2026-06-27T02:03:41.408Z",
      "location_count": 15,
      "location_summary": "Atlanta, Georgia • Maywood, Illinois • Iowa City, Iowa + 7 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Maywood",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00428220"
    }
  ]
}